Kutatási jelek – Signal Engine

• Novel prostate cancer treatment can reduce risk of disease progression by half, clinical trial shows — Prostate cancer
• BRAF — Melanoma
• Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study — Melanoma
• FLAME: Osimertinib Plus Chemotherapy Improves PFS in ctDNA-Persistent NSCLC — NSCLC
• BREAKWATER Supports FDA Approval of Encorafenib-Cetuximab-FOLFIRI for BRAF V600E-Mutant mCRC — Colorectal cancer
• ASCO26: key readouts in lung cancer — NSCLC
• First-Line Odronextamab Shows High Complete Response Rate in DLBCL — Lymphoma
• ALK-Vac Anti-Tumor Resistance Vaccine Shows Promise in ALK+ NSCLC — NSCLC
• TP53 Database: Search on Tumor Variant Prevalence Data — TP53
• First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations — NSCLC
• Kidney Neoplasm — Renal cell carcinoma
• Decoding T-Cell Lymphoma: How Molecular Biology Is Driving a New Era of Targeted Treatment — Lymphoma
• Neladalkib Earns FDA Priority Review in ALK-Positive NSCLC — NSCLC
• Colorectal cancer risk linked to gut microbiome alterations — Colorectal cancer
• Neuroblastoma — Neuroblastoma
• Lorlatinib Shows Promise in ALK Driven Neuroblastoma — Neuroblastoma
• Becotatug Vedotin: First EGFR-Targeted ADC Approved in China for Recurrent or Metastatic Nasopharyngeal Carcinoma — Nasopharyngeal carcinoma
• EA5162 Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR — NSCLC
• Cholangiocarcinoma Workup: Laboratory Studies, Imaging Studies, Procedures — Cholangiocarcinoma
• EML4 EMAP like 4 — NSCLC